EUVIMEDEUVIMED entdecken
Crossref

Three cases of severe drug-induced liver injury caused by abiraterone acetate in advanced metastatic prostate cancer

Yoshihiro Nakagami, Toshiki Mugita, Ayana Doguchi, Masahiro Kurokawa, Sho Okada, Tatsuki Inoue, Madoka Omizu, Kazuhiko Oshinomi, Masakazu Nagata, Takashi Fukagai

The Showa Medical University Journal · 2025

DOI: 10.15369/smuj.37.3_141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Showa Medical University Journal, 2025. Verfasst von Yoshihiro Nakagami und 9 weiteren Autor:innen. Die Arbeit nennt 14 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Abiraterone acetate is used to treat high-risk hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer.However, drug-induced liver injury is a complication of abiraterone acetate administration.Drug-induced liver injury can be categorized as hepatocellular, cholestatic, or mixed type based on the R ratio derived from the ratio of alanine aminotransferase to alkaline phosphatase.Case 1 : An 87-year-old man experienced liver injury caused by abiraterone acetate treatment of metastatic hormone-sensitive prostate cancer.Grade 4 aspartate aminotransferase and alanine aminotransferase increasing were observed for 6 weeks after treatment.The R ratio was 27.5 ; therefore, the drug-induced liver injury was diagnosed as the hepatocellular type.Case 2 : A 66-year-old man experienced liver injury caused by abiraterone acetate treatment of metastatic castration-resistant prostate cancer.Four weeks after treatment, Grade 3 aspartate aminotransferase, Grade 4 alanine aminotransferase, and Grade 3 γ-glutamyl transpeptidase increasing were observed.The R ratio was 7.0 ; therefore, the drug-induced liver injury was diagnosed as the hepatocellular type.Case 3 : A 74-year-old man experienced liver injury caused by abiraterone acetate treatment of metastatic hormone-sensitive prostate cancer.Four weeks after treatment, Grade 3γ-glutamyl transpeptidase and Grade 3 alkaline phosphatase increasing were observed.The R ratio was 0.4 ; thus, the drug-induced liver injury was diagnosed as cholestatic type.Severe drug-induced liver injury is a potential complication of abiraterone acetate therapy.Monitoring of liver function is recommended at least every 2 weeks for the first 3 months of treatment.

Zitieren

APA

Nakagami, Y., Mugita, T., Doguchi, A., Kurokawa, M., Okada, S., Inoue, T., Omizu, M., Oshinomi, K., Nagata, M., & Fukagai, T. (2025). Three cases of severe drug-induced liver injury caused by abiraterone acetate in advanced metastatic prostate cancer. The Showa Medical University Journal. https://doi.org/10.15369/smuj.37.3_141

Vancouver

Nakagami Y, Mugita T, Doguchi A, Kurokawa M, Okada S, Inoue T, et al. Three cases of severe drug-induced liver injury caused by abiraterone acetate in advanced metastatic prostate cancer. The Showa Medical University Journal. 2025. doi:10.15369/smuj.37.3_141

BibTeX
@article{Nakagami2025,
  author = {Nakagami, Yoshihiro and Mugita, Toshiki and Doguchi, Ayana and Kurokawa, Masahiro and Okada, Sho and Inoue, Tatsuki and Omizu, Madoka and Oshinomi, Kazuhiko and Nagata, Masakazu and Fukagai, Takashi},
  title = {Three cases of severe drug-induced liver injury caused by abiraterone acetate in advanced metastatic prostate cancer},
  journal = {The Showa Medical University Journal},
  year = {2025},
  doi = {10.15369/smuj.37.3_141}
}
Kostenlos starten →